Quoin Pharmaceuticals Ltd DRC (QNRX) - Net Assets
Based on the latest financial reports, Quoin Pharmaceuticals Ltd DRC (QNRX) has net assets worth $-1.21 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.42 Million) and total liabilities ($7.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Quoin Pharmaceuticals Ltd DRC to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.21 Million |
| % of Total Assets | -18.91% |
| Annual Growth Rate | 14.6% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 361.45 |
Quoin Pharmaceuticals Ltd DRC - Net Assets Trend (2015–2024)
This chart illustrates how Quoin Pharmaceuticals Ltd DRC's net assets have evolved over time, based on quarterly financial data. Also explore Quoin Pharmaceuticals Ltd DRC asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Quoin Pharmaceuticals Ltd DRC (2015–2024)
The table below shows the annual net assets of Quoin Pharmaceuticals Ltd DRC from 2015 to 2024. For live valuation and market cap data, see market value of Quoin Pharmaceuticals Ltd DRC.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $9.20 Million | +62.51% |
| 2023-12-31 | $5.66 Million | -23.53% |
| 2022-12-31 | $7.41 Million | +1027.31% |
| 2021-12-31 | $657.03K | +109.94% |
| 2020-12-31 | $-6.61 Million | -253.82% |
| 2019-12-31 | $4.30 Million | +15.29% |
| 2018-12-31 | $3.73 Million | -31.39% |
| 2017-12-31 | $5.43 Million | -26.63% |
| 2016-12-31 | $7.40 Million | +174.27% |
| 2015-12-31 | $2.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Quoin Pharmaceuticals Ltd DRC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4992247800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $64.37 Million | 699.32% |
| Total Equity | $9.20 Million | 100.00% |
Quoin Pharmaceuticals Ltd DRC Competitors by Market Cap
The table below lists competitors of Quoin Pharmaceuticals Ltd DRC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tonkens Agrar AG
XETRA:GTK
|
$10.04 Million |
|
SONOKONG Co. Ltd
KQ:066910
|
$10.04 Million |
|
SaveLend Group AB
ST:YIELD
|
$10.05 Million |
|
Adcore Inc
TO:ADCO
|
$10.05 Million |
|
Pharmena S.A.
WAR:PHR
|
$10.02 Million |
|
ERWE Immobilien AG
F:ERWE
|
$10.02 Million |
|
Marine Petroleum Trust
NASDAQ:MARPS
|
$10.02 Million |
|
Baru Gold Corp
V:BARU
|
$10.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quoin Pharmaceuticals Ltd DRC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,664,016 to 9,204,673, a change of 3,540,657 (62.5%).
- Net loss of 8,962,472 reduced equity.
- Other factors increased equity by 12,503,129.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.96 Million | -97.37% |
| Other Changes | $12.50 Million | +135.83% |
| Total Change | $- | 62.51% |
Book Value vs Market Value Analysis
This analysis compares Quoin Pharmaceuticals Ltd DRC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $76107.08 | $6.21 | x |
| 2016-12-31 | $170665.83 | $6.21 | x |
| 2017-12-31 | $101863.03 | $6.21 | x |
| 2018-12-31 | $60457.00 | $6.21 | x |
| 2019-12-31 | $42421.48 | $6.21 | x |
| 2020-12-31 | $-11549.00 | $6.21 | x |
| 2021-12-31 | $411.42 | $6.21 | x |
| 2022-12-31 | $641.89 | $6.21 | x |
| 2023-12-31 | $220.04 | $6.21 | x |
| 2024-12-31 | $68.71 | $6.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quoin Pharmaceuticals Ltd DRC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.71x
- Recent ROE (-97.37%) is above the historical average (-297.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -97.00% | 0.00% | 0.00x | 1.27x | $-2.89 Million |
| 2016 | 206.94% | 0.00% | -0.03x | 1.19x | $14.58 Million |
| 2017 | 187.32% | 0.00% | 0.00x | 1.61x | $9.63 Million |
| 2018 | 411.09% | 0.00% | -0.05x | 1.48x | $14.94 Million |
| 2019 | -36.33% | 0.00% | 0.00x | 1.44x | $-1.99 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.43 Million |
| 2021 | -3266.60% | 0.00% | 0.00x | 14.24x | $-21.53 Million |
| 2022 | -126.66% | 0.00% | 0.00x | 1.95x | $-10.12 Million |
| 2023 | -153.36% | 0.00% | 0.00x | 2.15x | $-9.25 Million |
| 2024 | -97.37% | 0.00% | 0.00x | 1.71x | $-9.88 Million |
Industry Comparison
This section compares Quoin Pharmaceuticals Ltd DRC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quoin Pharmaceuticals Ltd DRC (QNRX) | $-1.21 Million | -97.00% | N/A | $10.04 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Net… Read more